Y-mAbs Therapeutics, Inc. (YMAB)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 19,525 | 20,904 | 18,461 | 22,798 |
| Gross profit | 16,863 | 17,903 | - | - |
| Cost of goods sold | 2,662 | 3,001 | 2,248 | 3,014 |
| Selling, general, and administrative | 11,313 | 13,087 | 13,613 | 17,232 |
| License royalties | 50 | - | - | - |
| Research and development | 11,104 | 11,359 | 11,168 | 12,341 |
| Total operating costs and expenses | 22,467 | 24,446 | 27,029 | 32,587 |
| Loss from operations | -5,604 | -6,543 | -8,568 | -9,789 |
| Interest and other income | 2,372 | 1,352 | 1,916 | 640 |
| Loss before income taxes | -3,232 | -5,191 | -6,652 | -9,149 |
| Provision for income taxes | 7 | 5 | 346 | 100 |
| Net loss | -3,239 | -5,196 | -6,998 | -9,249 |
| Foreign currency translation | -2,013 | -863 | -1,083 | 199 |
| Comprehensive loss | -5,252 | -6,059 | -8,081 | -9,050 |
| Earnings per share, basic | -0.07 | -0.12 | -0.16 | -0.21 |
| Earnings per share, diluted | -0.07 | -0.12 | -0.16 | -0.21 |
| Weighted average number of shares outstanding, basic | 45,318,000 | 45,104,476 | 44,626,943 | 44,022,356 |
| Weighted average number of shares outstanding, diluted | 45,318,000 | 45,104,476 | 44,626,943 | 44,022,356 |